Evaluation of Lipid Profile and Inflammatory Parameters in Female Diabetes Type 2 Induced Rabbits Treated with Glimepride, Bromocriptine and Fluoxtein
Article Sidebar
Main Article Content
Abstract
This study was performed to evaluate the improvement in serum lipid profile and inflammatory parameters in female diabetic rabbits after two-month treatment with glimepride, bromocriptine, and fluoxtein in order to decrease the cardiovascular disease risk related to type 2 diabetes mellitus. Twenty-five local female rabbits were divided equally into five groups; four groups were diabetes type 2 induced by alloxan 120 mg/kg and nicotinamide 50 mg/kg, and the fifth group was control negative (Cv-). The animals were allocated to different treatment regimens, dosed orally on a daily basis for two months, as follows: T1 (glimepride 0.11 mg/kg),T2 (glimepride 0.11+bromocriptine 0.04 mg/kg),T3 (glimepride 0.11+fluoxtein 0.29 mg/kg), control positive group(Cve+) diabetic without treatment, and the fifth group was a control negative group (Cve-) dosed with distall water. Lipid profile, interleukin-6, and C-reactive protein were determined after diabetes induction and at the end of the experiment. IL-6 was significantly reduced in T2, while C-Reactive Protein was not significantly reduced. All treated groups showed nearly similar total cholesterol levels, demonstrating the higher level of high density lipoprotein-C level . At the same time, all treated groups showed a non-significant decrease in low density lippoprotein-C, and T2 showed superiority in reducing very low density lipoprotein-C and triglyceride levels over all other diabetic groups. In conclusion, diabetes agonist (Bromocriptine)+glimepride demonstrated superiority over the combination therapy glimepride+flouxtein and glimepride as monotherapy in improving diabetes type 2 related cardiovascular complications.
Received: 22/10/2018
Accepted: 23/12/2018
Publishing: 31/1/2019
Downloads
Article Details
How to Cite
References
American Diabetes Association(2014). Archived from the original on 14 February 2014. Retrieved 24 April 2014.
Chen, L.; Magliano, D.J.; Zimmet, P.Z. (2014) .The worldwide epidemiology of type 2 diabetes mellitus: present and future perspectives. Nature reviews endocrinology. ,8(4):228-36. https://doi.org/10.1038/nrendo.2011.183
DMICC (2014) .Genetic basis of type 1 and type2 diabetes, obesity, and their complications. Advances and emerging opportunities in diabetes research: a Strategic Planning report of the DMICC.
Whiting, D.R.; Guariguata, L.; Weil, C.; Shaw, J.(2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract.;94(3):31121. https://doi.org/10.1016/j.diabres.2011.10.029
Sio¨holm, A .;Nystro¨m, T.(2006). Inflammation and the etiology of type 2 diabetes ,Diabetes Metab Res Rev .,22(1):4-10.
https://doi.org/10.1002/dmrr.568
Elsner, M.; Tiedge, M.; Guldbakke, B.; Munday, R.; and Len-zen, S.(2002). Importance of GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan. Diabetologia., 45(11): 1542-1549. https://doi.org/10.1007/s00125-002-0955-x
Lenzen, S.(2008). The mechanisms of alloxan- and streptozotocin-induced Diabetologia., 51(2): 216-26. diabetes.
https://doi.org/10.1007/s00125-007-0886-7
Hafez, E. S. E.(1970). Reproductive and breeding. Techniques For Laboratory animals. Lea and Fibiges,philadilphia.pp:275.
Vattam, K.K.; Raghavendran, H.R.B.; Murali, M.R.; Savatey, H.; Kamarul, T.(2015). Coadministration of alloxan and nicotinamide in rats produ -ces ces biochemical changes in blood and pathological alterations comparable to the changes in type II diabetes mellitus. Human and Experimental Toxicology. , 35 ( 8): 893-901. https://doi.org/10.1177/0960327115608246
Sanofi- Aventis U.S.LLC(2013). Highlight prescribing informationRx.
Meda pharma (2018). Parlodel inserted leaflet.
Actavis,Barnstaple,EX32,UK(2015).Fluoxten inserted leaflet.
Friedewald, W.T.; Levy, R.I,.;Fredrickson, D.S.(1972).. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem .,18(6):499-502. https://doi.org/10.1093/clinchem/18.6.499
Snedecor, G.W.; and Cochran, W.G. (1973). Statistical Methods. 6th edition ,the Iowa state University press., pp: 238-248.
Krysiak, R.; Samborek ,M.; Stojko, R.(2014).Anti-inflammatory effect of bromocriptine in a patient with autoimmune polyglandular syndrome type 2 Leet.,35(3):17982.
Pickup, J.C.; Crook, M.A.(1998). Is type II diabetes mellitus a disease of the innate immune system? Diabetologia ., 41(10): 1241-1248.
https://doi.org/10.1007/s001250051058
Xu, H.; Barnes, G.T.; Yang, Q, et al(2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest ., 112(12): 1821-1830. https://doi.org/10.1172/JCI200319451
Kashinakunti,S.V.; Rangappa,M.; and Kallaganada,G.S.(2016). Serum High Sensitive - C Reactive Protein Levels in Type 2 Diabetes Mellitus -A Case Control Study ,Int.J. Biochem. Res. Rev.,11(4): 1-8. https://doi.org/10.9734/IJBCRR/2016/25305
Abbas, A.K.; Maitra, A.(2005). The endocrine Pancreas. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease, 7th ed. New Delhi: Elsevier. ;1189-1207.
Gohel, M.G.; Chacko, A.N.(2013). Serum GGT activity and hs-CRP level in patients with type 2 diabetes mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control of Diabetes & Metabolic Disorders. ,12:56. Published online 2013 Dec 20. doi: 10.1186/2251-6581-12-56. https://doi.org/10.1186/2251-6581-12-56
Levinson, W. (2004). Medical Microbiology and Immunology, 8th ed. New York: McGraw Hill. 2004;113.
Takebayashi, K.; Aso, Y.; Inukai ,T.(2004). Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism. ,53(6):693-699. https://doi.org/10.1016/j.metabol.2004.01.003
Camhi, S.M.; Stefanick ,M.L.; Ridker, P.M.; Young, D.R.(2009). Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome. Metabolism. ,59(1):54-61. https://doi.org/10.1016/j.metabol.2009.07.008
Chambers, J.C.; et al. (2001). C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation. ,104(2):145-150. https://doi.org/10.1161/01.CIR.104.2.145
Ford, E.S. (1999). Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care., 22(12):1971-1977.
https://doi.org/10.2337/diacare.22.12.1971
Yudkin, J.S.; Stehouwer, C.D.A.; Emeis, J.J.; and Coppack, S.W. (1999). C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol., 19(4):972-978. https://doi.org/10.1161/01.ATV.19.4.972
Pepys, M.B.; Hirschfield, G.M.(2003). Creactive protein: a critical update. J Clin Invest .,112(2):299. https://doi.org/10.1172/JCI18921C1
Benedict, C.R.; Mathew, B.; Rex, K.A.; Cartwright, J. & Sordahl, L.A. (1986). Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circ Res.,58(1): 58-67.
https://doi.org/10.1161/01.RES.58.1.58
Jain,H.R.; Shetty,V.; Singh,G.S.; Shetty,S.(2016). A Study of Lipid Profile in Diabetes Mellitus. International Journal of Scientific Study .,Vol 4 ( 9):56-61.
Sultania, S.; Thakur ,D.; Kulshreshtha, M.(2017). Study of Lipid Profile in Type 2 Diabetes Mellitus Patients and its Correlation with HbA1c. International Journal of Contemporary Medical Research., Volume 4(2): 2454-7379.
Tsunekawa, et al (2003). Plasma Adiponectin plays an important role in improving Insulin resistance with Glimepiride in elderly Type Diabetes Mellitus Subjects , Diabetes Care ., Vol.26(2):285-289. https://doi.org/10.2337/diacare.26.2.285
Nguyan, C.; Pan, J.; Charles, M.A.(1998). Drugs today (Bare).,34(5):391-400. https://doi.org/10.1358/dot.1998.34.5.472189
Indirakumari ,N.; Vinutha, S .; Kambar,C.(2015). Study of Lipid Profile in Diabetes Mellitus Patients Who Were On Glibenclamide and Glimeperide. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)., 14 (1):13-22.
Van greevenbroek, M.M.; Schalkwijk ,C.G.;Stehouwer,C.D.(2013).Obesity-associated low-grade inflammation in type 2 diabetes mellitus:ccauses and consequences .Neth J Med.,71(4):174-87.
Fitzgerald,P.; DinanT.G,(2008). Prolactin and dopamine: What is the connection? AReview Article ; Journal of Psychopharmacology., Vol 22( 2):12-19. https://doi.org/10.1177/0269216307087148